Form 4: Gossamer Bio Reprices CCO Stock Options to $0.45

Gossamer Bio, Inc. has repriced Chief Commercial Officer Robert Paul Smith JR's stock options, significantly reducing their exercise price to $0.45 per share.

Summary

• Robert Paul Smith JR, Chief Commercial Officer of Gossamer Bio, Inc., was the reporting person for this transaction.
• The transaction date for the repricing was March 19, 2026.
• The company approved a one-time repricing of certain outstanding stock options granted under its 2019 Incentive Award Plan.
• The repricing reduced the per share exercise price of these options to $0.45.
• Specifically, 562,500 stock options with an original exercise price of $2.88 were repriced.
• Additionally, 572,000 stock options with an original exercise price of $1.13 were repriced.
• Following the repricing, Robert Paul Smith JR beneficially owns 1,134,500 stock options, all with an exercise price of $0.45.
• All other terms and conditions of the repriced options, including vesting and term, remain in full force and effect.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for existing shareholders, as it suggests significant past stock underperformance and potential future dilution, even while aiming to re-incentivize key management.

Positives

• The repricing aims to restore the incentive value of the stock options for the Chief Commercial Officer, potentially increasing motivation and retention.
• Aligns executive compensation more closely with the company's current stock performance, making the options more likely to be 'in-the-money' or closer to it.

Negatives

• The necessity for repricing indicates that the company's stock price has significantly underperformed, rendering the original options 'underwater'.
• Can be perceived negatively by existing shareholders as it potentially dilutes their ownership if the stock price recovers above the new exercise price.
• May raise questions about the effectiveness of the original incentive structure and overall company performance.

Risks

• Potential for shareholder dissatisfaction due to the perceived benefit to executives following stock underperformance.
• Negative market perception regarding the company's stock performance that necessitated the repricing.
• Increased compensation expense if the stock price rises above the new exercise price, leading to option exercise.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the terms of the repriced options.

Industry Context

StockSavvy.ai notes that option repricing is a common practice in industries, particularly biotechnology, where stock volatility can lead to underwater options. It is often employed to retain key talent when stock performance lags, but can be viewed critically by shareholders due to its dilutive potential and implications of past underperformance.

Comparison to Industry Standards

• Option repricing is a known strategy, especially in the biotechnology sector where long R&D cycles and high market volatility can frequently lead to stock options becoming underwater.
• Companies such as Biogen (BIIB) and Amgen (AMGN) have historically undertaken similar repricing initiatives during periods of significant stock underperformance to re-incentivize executives and key employees.
• The specific terms of this repricing, reducing the strike price to $0.45, would need to be compared against Gossamer Bio's current market price and peer group repricing events to fully assess its relative generosity or necessity.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution if the stock price recovers above the new exercise price; may view the repricing negatively due to past stock underperformance and executive benefit.
• Employees (specifically Robert Paul Smith JR): Increased incentive and motivation due to options becoming 'in-the-money' or closer to it, improving retention.

Key Dates

Recommendation

The repricing of executive stock options indicates past stock underperformance, which is a negative signal. However, it also serves to re-incentivize key management, which could be a positive for future performance. Without broader financial context or strategic updates, a 'hold' recommendation is appropriate, suggesting investors monitor future company performance and market reaction.

Keywords

Gossamer Bio, GOSS, Stock Options, Option Repricing, Executive Compensation, Form 4, Insider Transaction, Biotechnology, Incentive Award Plan